Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026)

Krystal Biotech has disclosed Income from Continuing Operations across 11 years of filings, most recently posting 55932000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 55932000.0, up 56.53% year-over-year; the trailing twelve-month figure through Mar 2026 was 225072000.0 (up 81.52% YoY), and the FY2025 annual result was 204831000.0, up 129.74% from the prior year.
• Income from Continuing Operations came in at 55932000.0 for Q1 2026 at Krystal Biotech, up from 51400000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 80747000.0 in Q3 2023 to a low of 49965000.0 in Q1 2022.
• The 5-year median for Income from Continuing Operations is 15568000.0 (2024), against an average of 12997352.94.
• Across the five-year window, Income from Continuing Operations sank 215.99% in 2022 and soared 3734.01% in 2025, its largest moves.
• Krystal Biotech's Income from Continuing Operations stood at 32052000.0 in 2022, then soared by 127.12% to 8692000.0 in 2023, then jumped by 423.62% to 45513000.0 in 2024, then rose by 12.93% to 51400000.0 in 2025, then advanced by 8.82% to 55932000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 55932000.0 (Q1 2026), 51400000.0 (Q4 2025), and 79365000.0 (Q3 2025), per Business Quant data.